Epidemiology & Clinical Relevance
Anal fissures represent one of the most common causes of anorectal pain and hematochezia, affecting approximately 1 in 10 individuals at some point in life, with peak incidence in young to middle adulthood (20–40 years). Although both sexes are affected, posterior midline fissures predominate in women (due to childbirth-related trauma and anatomical differences), while anterior midline fissures occur more frequently in men. Acute fissures account for ~75% of cases; the remainder present as chronic fissures (>8–12 weeks duration), often associated with failed healing pathways.
Clinically, fissures are broadly categorized as:
- Typical (primary) fissures: Result from mechanical trauma due to passage of hard stool, transient sphincter hypertension (>65 mmHg resting pressure), or reflex spasm.
- Atypical (secondary) fissures: Associated with systemic conditions including Crohn’s disease (~10–20% of IBD-related anorectal disease), HIV, tuberculosis, syphilis, leukemia, CMV colitis, or anal carcinoma. These often present with non-midline location, multiple fissures, posterior/anterior and lateral involvement, or failure to respond to standard therapy.
Key Insight: A fissure not healing within 6–8 weeks should prompt evaluation for underlying etiology—especially in patients >50 years or with “red flag” features (weight loss, night diarrhea, family history of colorectal cancer, perianal fistulae, or ulcerative colitis/Crohn’s).
Pathophysiology: Beyond Simple Trauma
The current model emphasizes a vicious cycle:
- Hard stool → tear in anoderm (Zone III–IV transition zone at posterior midline due to poor vascularity and high baseline sphincter tone).
- Tear → noxious stimulation of nociceptors → pain → reflex internal anal sphincter (IAS) spasm.
- Sphincter spasm → increased resting pressure & reduced perfusion → impaired healing → fibrosis → chronic fissure.
In chronic disease, histopathology reveals:
- Fibromuscular septum: Collagen deposition and myofibroblast proliferation within the fissure base.
- Hypertrophied papilla: Hyperplasia of anal papillae at the proximal rim due to chronic irritation (a useful diagnostic clue).
- Sentinel tag: Epidermalized skin tag from lymphatic obstruction and granulation tissue formation.
Imaging Insight: High-resolution anorectal manometry (HRARM) shows elevated resting pressure (>80 mmHg) in >90% of chronic cases, supporting the use of sphincter-relaxing agents. MRI elastography is emerging to quantify fissure stiffness and predict response to botulinum toxin.
Diagnostic Evaluation: Stepwise Approach with Clinical Pearls
1. History & Physical Exam
- Classic presentation: Severe, stabbing pain during defecation followed by prolonged post-defecatory pain (10–30 min), often described as “tearing” or “cutting,” accompanied by bright red blood on toilet paper.
- Red flags for atypical etiology:
- Anterior fissure in women: consider obstetric trauma vs. Crohn’s.
- Lateral or multifocal fissures: strongly suggest IBD, HIV, or neoplasia.
- Ulcerations extending beyond the anoderm (beyond dentate line): suspicious for malignancy or deep abscess.
2. Visual Inspection
- Perform with patient in left lateral position; gently separate buttocks without forcing—avoid digital exam if acute pain is severe.
- Acute fissure: linear, superficial epithelial defect with clean margins, often at 6 o’clock (posterior) or 12 o’clock (anterior).
- Chronic fissure: elevated, rolled edges; visible sphincter fibers at base; sentinel tag at anal verge; hypertrophied papilla on anoscopy.
3. Procedural Considerations
- Digital rectal exam (DRE): Often poorly tolerated acutely—delay until after topical anesthetic (e.g., lidocaine 5% gel applied 10 min prior) if clinically indicated.
- Anoscopy: Essential for chronic/recurrent cases to assess fissure morphology and exclude mucosal lesions. Perform under local anesthesia (infiltration or topical) if patient cannot tolerate.
- Diagnostic ambiguity? Proceed to:
- Rectal exam under anesthesia (REUA) + full-thickness biopsy: indicated for suspected Crohn’s, cancer, or atypical ulcers.
- MRI pelvis: Evaluates fistula-in-ano, abscess, or deep tissue involvement—especially if fissure is lateral or recurrent post-treatment.
- Colonoscopy: Recommended in patients >45 years with new-onset symptoms, especially with risk factors for CRC or IBD.
Guideline Note (ASGE 2023): Biopsy is mandatory for fissures not healing after 8–12 weeks of optimal medical therapy to exclude malignancy, Crohn’s, or tuberculosis in endemic regions.
Management: Evidence-Based, Risk-Stratified Approach
I. First-Line Conservative Therapy (Strong Recommendation | GRADE A)
| Intervention | Mechanism & Evidence | Dosing/Duration | Clinical Pearls |
|---|---|---|---|
| High-fiber diet + hydration | Increases stool bulk, reduces intraluminal pressure. Meta-analysis (Cochrane 2022) shows fiber supplementation increases healing rates vs placebo (RR 2.1; 95% CI 1.6–2.8). | Psyllium 3–5 g/day + ≥2 L water/day. Avoid wheat bran if bloating. | Start low dose to minimize gas/bloating. |
| Stool softeners/laxatives | Osmotic agents (PEG 17g/day) preferred over stimulant laxatives (risk of dependency). Mineral oil may reduce pain acutely but avoid long-term use (lipid pneumonia risk). | PEG: 17g daily; docusate: limited evidence. | Avoid bulk-forming agents in acute spasm. |
| Warm sitz baths | Vasodilation, sphincter relaxation, improved local perfusion. RCTs show adjunctive use ↑ healing by 30–40%. | 2–3x/day for 15–20 min after defecation. | Combine with topical meds for synergistic effect. |
| Topical nitrates (GTN 0.4%) | NO donor → IAS relaxation, vasodilation. Healing rates ~50–60% at 8 weeks. | 1/2 inch intra-anally BID × 8 weeks. Taper if asymptomatic. | Headache in >70%; limit duration to avoid tolerance. Avoid phosphodiesterase-5 inhibitors (e.g., sildenafil) due to hypotension risk. |
| Topical calcium channel blockers (CCBs) | Block Ca²⁺ influx → smooth muscle relaxation. Meta-analysis (Br J Surg 2023) shows nifedipine 2% non-inferior to GTN with fewer side effects (RR 0.6 for adverse events). | Diltiazem 2% or nifedipine 2% BID × 8–12 weeks. | Compounded formulations vary in bioavailability—verify concentration. Avoid oral CCBs for fissures (insufficient local concentration). |
| Topical anesthetics | Symptomatic relief only—no healing benefit. | Lidocaine 2–5% gel BID/TID PRN pain. | Avoid prolonged use (>2 weeks): risk of sensitization, methemoglobinemia in infants. |
Combination Therapy: GTN + lidocaine improves tolerability; CCB + fiber yields highest efficacy (healing ~65% at 12 weeks). Do not combine nitrates with CCBs—additive hypotension risk.
II. Second-Line: Minimally Invasive Therapies
| Intervention | Evidence Base | Technique & Dosing | Efficacy/Safety |
|---|---|---|---|
| Botulinum toxin A (BoNT-A) | RCTs (e.g., NEJM 2019) show 50–70% healing at 8–12 weeks vs 30–40% with placebo. Non-inferior to ISD in healing, but reversible effect allows repeat dosing. | 20–30 units injected into IAS (4 sites: 3 & 9 o’clock, 1 cm above fissure base). Avoiddentate line to prevent sensory deficit. | Healing onset at 7–10 days. Transient gas incontinence (5–10%), no permanent fecal incontinence in trials. Contraindicated in infection or neuromuscular disorders. |
| Fissurectomy | Removes fibrotic tissue, promotes granulation. Often combined with BoNT-A to reduce recurrence. Open fissurectomy + BoNT-A: 85% healing at 16 weeks (Int J Colorectal Dis 2024). | Debride edges + base → curette fissure bed. May include removal of sentinel tag/papilla. | Ideal for chronic fissures with prominent fibrosis. Lower incontinence risk vs LIS, but higher recurrence (~15–20%). |
III. Definitive Surgical Therapy
| Procedure | Indications & Evidence | Technique Notes | Outcomes |
|---|---|---|---|
| Lateral Internal Sphincterotomy (LIS) | First-line surgery for chronic fissures unresponsive to ≥8 weeks of optimized medical therapy. Healing rates: 90–95%. Recurrence: <5%. | Closed LIS: Incision at anal verge, blunt dissection of IAS fibers to dentate line. Open LIS: Direct visualization via V-mucosal flap. Tailored sphincterotomy: Limited to fissure length (e.g., 1–2 cm) if fissure is short—reduces incontinence risk without compromising healing. | Stress incontinence: ~5% (vs 0.5% baseline). Liquid stool leakage most common; solid control usually preserved. Absolute contraindication: Pre-existing sphincter deficiency. |
| Fissurectomy + Anoplasty | Sphincter-sparing option for patients at high incontinence risk (e.g., multiparous women, prior anorectal surgery). | Excision of fissure + advancement flap (e.g., V-Y plasty) to cover defect. | Healing: 75–85%. Higher recurrence than LIS but lower incontinence risk (<2%). Best for lateral/complex fissures. |
Surgical Decision Aid (ECCO 2024):
- Low-risk patients: Proceed with LIS.
- High-risk for incontinence (e.g., elderly, neurogenic bowel): Offer BoNT-A or fissurectomy-first approach.
- Recurrent fissures: MRI pelvis first to exclude fistula—LIS contraindicated if fistula present.
IV. Avoided/Discontinued Therapies
- Anal dilatation (Lord procedure): Historical use abandoned due to high rates of permanent fecal incontinence (up to 50% at 5 years) and sphincter avulsion. Not recommended by any current society guideline (ASGE/WGO/ACG).
- Topical steroid creams: No evidence for healing; may cause skin atrophy.
- Oral nifedipine: Ineffective—poor sphincter drug delivery.
Follow-Up & Monitoring Protocol
| Timepoint | Assessment Focus |
|---|---|
| 2–4 weeks | Pain reduction, bleeding cessation. If no improvement: optimize medical regimen (e.g., add CCB if GTN failed). |
| 8–12 weeks | End-point for medical therapy success. Non-healing → imaging/biopsy; consider BoNT-A or LIS. |
| 6 months post-LIS/BoNT-A | Evaluate for recurrence (<5%) or new-onset incontinence. Refer to pelvic floor PT if subtle leakage develops. |
Recurrence Red Flags: >1 recurrence → evaluate for IBD, Crohn’s (fecal calprotectin, serology), or sphincter dysfunction via HRARM.
Conclusion: Modern management prioritizes stepwise escalation from lifestyle modifications to targeted pharmacotherapy and sphincter-directed interventions—always balancing healing efficacy against incontinence risk. The integration of HRARM, MRI, and histopathology in refractory cases enables precision diagnosis and optimal outcomes. With adherence to evidence-based algorithms, >90% of chronic fissures can be resolved without permanent functional compromise.
Sources: American Society for Gastrointestinal Endoscopy (ASGE) Guidelines 2024; European Crohn’s and Colitis Orga
